Lundbeckfonden Ventures logo

Lundbeckfonden Ventures

Europe, Hovedstaden, Denmark, Copenhagen

Description

Lundbeckfonden Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by Lundbeck Foundation

Investor Profile

Lundbeckfonden Ventures has made 63 investments, with 1 in the past 12 months and 33% as lead.

Stage Focus

  • Series B (24%)
  • Series C (24%)
  • Series A (22%)
  • Series Unknown (17%)
  • Debt Financing (3%)
  • Series D (3%)
  • Series E (2%)
  • Series F (2%)
  • Seed (2%)
  • Grant (2%)

Country Focus

  • United States (52%)
  • United Kingdom (13%)
  • France (11%)
  • Denmark (10%)
  • The Netherlands (3%)
  • Israel (3%)
  • Spain (3%)
  • Sweden (3%)
  • Finland (2%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical
  • Biopharma
  • Life Science
  • Medical Device
  • Manufacturing
  • Clinical Trials
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Lundbeckfonden Ventures frequently co-invest with?

Omega Funds
Europe, Geneve, Switzerland, Geneva
Co-Investments: 5
Pfizer Venture Investments
North America, New York, United States, New York
Co-Investments: 7
Alexandria Venture Investments
North America, California, United States, Pasadena
Co-Investments: 6
Ysios Capital
Europe, Pais Vasco, Spain, San Sebastian
Co-Investments: 6
Bay City Capital
North America, California, United States, San Francisco
Co-Investments: 5
Seventure Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 6
New Enterprise Associates
North America, California, United States, Menlo Park
Co-Investments: 15
Arix Bioscience
Europe, England, United Kingdom, London
Co-Investments: 6
SR One
North America, Massachusetts, United States, Cambridge
Co-Investments: 10
OUP (Osage University Partners)
North America, Pennsylvania, United States, Bala Cynwyd
Co-Investments: 5

What are some of recent deals done by Lundbeckfonden Ventures?

Kvantify

Copenhagen, Hovedstaden, Denmark

Kvantify provides Quantum computing and HPC software solutions that address hard computational challenges.

Artificial Intelligence (AI)Cloud ComputingFinTechInformation TechnologyLife ScienceMachine LearningQuantum ComputingSoftware
SeedJul 3, 2024
Amount Raised: $10,744,047
Notify Therapeutics

Copenhagen, Hovedstaden, Denmark

Notify Therapeutics develops therapies for the treatment of infertility.

BiotechnologyLife ScienceMedicalTherapeutics
Series UnknownSep 25, 2023
Amount Raised: $5,295,713
Women in Life Science Denmark

Copenhagen, Hovedstaden, Denmark

WiLD is a networking platform for women in senior positions in business and academia that is motivating and focused on science.

Life ScienceNon ProfitWomen's
GrantJun 13, 2023
Amount Raised: $68,838
VarmX

Leiden, Zuid-Holland, The Netherlands

VarmX B.V. is manufacturing therapeutic proteins to instantaneously restore blood clotting in bleeding patients.

ManufacturingPharmaceuticalTherapeutics
Series BMay 25, 2023
Amount Raised: $36,950,090
LEXEO Therapeutics

New York, New York, United States

LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.

BiotechnologyLife ScienceTherapeutics
Series BSep 9, 2021
Amount Raised: $100,000,000
Aura Biosciences

Cambridge, Massachusetts, United States

Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.

BiotechnologyHealth CarePharmaceutical
Series UnknownMar 22, 2021
Amount Raised: $80,000,000
LEXEO Therapeutics

New York, New York, United States

LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.

BiotechnologyLife ScienceTherapeutics
Series AJan 7, 2021
Amount Raised: $85,000,000
Reneo Pharmaceuticals

San Diego, California, United States

Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases.

BiotechnologyMedicalPharmaceutical
Series BDec 9, 2020
Amount Raised: $95,000,000
VarmX

Leiden, Zuid-Holland, The Netherlands

VarmX B.V. is manufacturing therapeutic proteins to instantaneously restore blood clotting in bleeding patients.

ManufacturingPharmaceuticalTherapeutics
Series BJul 8, 2020
Amount Raised: $36,281,179
Amplyx Pharmaceuticals

San Diego, California, United States

Amplyx focuses on developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems

BiotechnologyClinical TrialsMedicalPharmaceutical
Series CMay 19, 2020
Amount Raised: $53,000,000